News & Articles

Read the full article >> The Evidence Base May 19, 2025 In large clinical trials, glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated significant effectiveness in improving glycemic control and reducing cardiovascular risk. However, recent concerns have arisen following reports suggesting a potential association between GLP-1 receptor agonists and increased risk of suicidal ideation (SI) and[…]

Read the full press release >> BOSTON–(BUSINESS WIRE)–OM1, a leading provider of AI-driven insights for life sciences and healthcare organizations, today announced a major milestone in the development of its groundbreaking PhenOM® Foundation Model. The model has now been trained on more than one billion years of patient health histories, representing the largest model of its[…]

Read the full media alert >> BOSTON–(BUSINESS WIRE)–OM1: What: OM1, the leader in real-world data and AI-driven insights in mental health for life sciences, announced an upcoming poster presentation hosted by Jessica Probst, OM1’s Principal, Real World Evidence. The poster focuses on the linkage between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and Suicidal Ideation (SI).[…]

Apr 22, 2025 9:01 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–OM1, the leader in real-world data and AI-driven insights for mental health, today announced a significant expansion of its specialty mental health network, adding over one million patients, making it the largest, most clinically rich network of its kind. This milestone deepens OM1’s ability to power[…]

Read the full press release >> March 12, 2025 09:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–OM1, a leading provider of real-world data (RWD) and AI-driven insights for life sciences, today announced its expansion into Europe to better support pharmaceutical and healthcare organizations with high-quality, AI-enhanced real-world evidence (RWE) solutions. This step marks a significant milestone[…]